NCT00219583CompletedPhase 2
A Phase 2b, Multi-Centre, Double-Blind, Placebo-Controlled, Parallel Group Dose Response Study To Assess The Efficacy and Safety Of Oral UK390,957 In Men With Premature Ejaculation
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Pfizer
- Enrollment
- 460
- Locations
- 50
- Primary Endpoint
- Assessment of efficacy and safety
Study Overview
Brief Summary
Assessment of efficacy and safety UK-390,957.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Premature ejaculation as defined by DSM-IV
Exclusion Criteria
- •History of erectile dysfunction
Outcomes
Primary Outcomes
Assessment of efficacy and safety
Secondary Outcomes
- Assessment of quality of sexual life
Investigators
Study Sites (50)
Loading locations...
Similar Trials
Completed
Phase 2
Assessment Of Efficacy and Safety UK-390,957 In Men With Premature EjaculationEjaculationNCT00219635Pfizer138
Completed
Phase 2
Oral Ciclosporin for Colonic Release in Ulcerative Colitis (CyCol™)Mild to Moderate Ulcerative ColitisNCT01033305Sigmoid Pharma118
Completed
Phase 2
Phase II Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 DiabetesNew Onset Type-1 DiabetesNCT02005848Kamada, Ltd.70
Terminated
Phase 2
A Study of ATL1102 or Placebo in Participants with Non-ambulatory Duchenne Muscular DystrophyDuchenne Muscular DystrophyNCT05938023Percheron Therapeutics48
Completed
Phase 2
To Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH) .Non-Alcoholic Steatohepatitis (NASH)NCT06168383Haisco Pharmaceutical Group Co., Ltd.186